Cardiovascular

Mouse studies suggest JAK inhibitors could help treat thrombosis in patients with JAK-2 mutations. In a mouse model of deep vein stenosis-induced thrombosis harboring a gain-of-function JAK-2 mutation, the JAK-1/JAK-2 inhibitor Jakafi ruxolitinib decreased neutrophil infiltration in clots and clotting rate compared with vehicle. Next steps include testing JAK inhibitors in thrombosis patients with JAK-2 mutations (see “JAKS and Clots”). ...